Cargando…
Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
Anemia is a major complication of chronic kidney disease (CKD), which mainly results from appropriate erythropoietin production impairment. Prolyl hydroxylase domain (PHD) inhibitors are currently being developed and approved in some countries as a new treatment for CKD patients with anemia due to t...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898206/ https://www.ncbi.nlm.nih.gov/pubmed/33628028 http://dx.doi.org/10.2147/TCRM.S293879 |